Please use this identifier to cite or link to this item:
https://doi.org/10.1016/S0022-5347(01)67113-1
DC Field | Value | |
---|---|---|
dc.title | Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy | |
dc.contributor.author | Esuvaranathan, K. | |
dc.contributor.author | Alexandroff, A.B. | |
dc.contributor.author | McIntyre, M. | |
dc.contributor.author | Jackson, A.M. | |
dc.contributor.author | Prescott, S. | |
dc.contributor.author | Chisholm, G.D. | |
dc.contributor.author | James, K. | |
dc.date.accessioned | 2011-11-30T06:21:03Z | |
dc.date.available | 2011-11-30T06:21:03Z | |
dc.date.issued | 1995 | |
dc.identifier.citation | Esuvaranathan, K., Alexandroff, A.B., McIntyre, M., Jackson, A.M., Prescott, S., Chisholm, G.D., James, K. (1995). Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. Journal of Urology 154 (2 I) : 572-575. ScholarBank@NUS Repository. https://doi.org/10.1016/S0022-5347(01)67113-1 | |
dc.identifier.issn | 00225347 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/29280 | |
dc.description.abstract | Purpose: To determine whether BCG therapy could upregulate interleukin-6 (IL-6) production in human transitional cell carcinomas (TCC). Materials and Methods: Immunohistochemistry of tumor biopsies and urinary cytospins and ELISA studies of urine from bladder cancer patients and TCC cell-line supernatants, before and after exposure to BCG, were performed. Results: Constitutive staining for IL-6 was found in the majority of bladder tumors. Interleukin-6 was detected in the urine of all 13 patients with carcinoma in situ and increased 5-fold during BCG therapy. Levels were variable but were greater in nonresponders (p <0.01). During therapy both detached bladder urothelial cells and polymorphonuclear leukocytes stained for IL-6. Production of IL-6 increased in only 3 cell lines after exposure to BCG, but all 7 cell lines showed increases after exposure to interferon-γ (p =0.015). Grade 3 cell lines showed much greater upregulation than grade 1 and 2 cell lines. Conclusions: The increase in IL-6 during BCG therapy may be caused by urothelial cells as well as leukocytes. The higher levels seen in nonresponders may be due to either higher grade or persisting tumor. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/S0022-5347(01)67113-1 | |
dc.source | Scopus | |
dc.subject | BCG vaccine | |
dc.subject | bladder neoplasms | |
dc.subject | interferon type II | |
dc.subject | interleukin-6 | |
dc.type | Article | |
dc.contributor.department | SURGERY | |
dc.description.doi | 10.1016/S0022-5347(01)67113-1 | |
dc.description.sourcetitle | Journal of Urology | |
dc.description.volume | 154 | |
dc.description.issue | 2 I | |
dc.description.page | 572-575 | |
dc.description.coden | JOURA | |
dc.identifier.isiut | A1995RJ05000070 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.